Federal Register
Patient-Level Data for Drugs and Biological Products Submissions Containing Real-World Data and Real-World Evidence; Request for Information- Facts included
- The Food and Drug Administration (FDA or Agency) is announcing a request for information (RFI) from interested parties to share perspectives on patient-level data access related to the use of real-world evidence (RWE) in regulatory decision-making for drugs and biological product submissions.
- The purpose of this RFI is to solicit input from interested parties on innovative solutions to address the challenges in submitting patient-level data for real-world data (RWD) analyzed in clinical studies included in a marketing application.
- Interested parties may include regulated industry, health information technology (HIT) vendors, academic medical centers, electronic data capture vendors, patient advocates, and other interested parties.
- Sourcing
- The source is a direct FDA announcement, which is a primary, authoritative source for regulatory communications.
- Framing
- The text is purely informational; it reports the FDA's RFI without editorializing or presenting opinion.
- Omissions
- The announcement does not explain the specific regulatory challenges that have prompted the RFI, nor does it detail how the FDA intends to use the information gathered, any timelines for response, or potential impacts on existing submission processes.
- Rhetorical notes (2)
- Framing · Audience Targeting